Investment Objective
The Primary Objective Of The Scheme Is To Provide Long-Term Capital Appreciation By Investing Predominantly In Equity And Equity Related Instruments Of Pharma And Healthcare Companies.
Hold this fund?
See it next to everything else you own: every holding in one place, how it is allocated and how it is really doing.
At a glance
If you had invested
Loading NAV history.
Portfolio
As of 8 Oct 2026
Asset class
Market cap
Key figures
How it compares
Trailing Returns
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 7Y | 10Y | |
|---|---|---|---|---|---|---|---|---|---|
| This fund | -2.60% | +2.82% | +23.50% | +19.83% | +18.83% | N/A | N/A | N/A | N/A |
Calendar Year Returns vs Benchmark
Comparison with BSE Healthcare Index
More detail
Monthly returns, rolling returns, risk measures and the full NAV history.
WhiteOak Capital Pharma and Heathcare Fund Regular Plan Growth is a Sector Specific - Pharma equity fund from WhiteOak Capital Asset Management Limited, launched on 30 Jan 2024. Its benchmark is the BSE Healthcare Index. The expense ratio is 2.80% a year. It manages ₹902 crore. The NAV was ₹16.06 on 8 Oct 2026.
| Period | Return | Volatility a year |
|---|---|---|
| Last 1 year | +18.83% | 15.32% |
Returns over 3 years and longer are compounded annual returns. Volatility is the annualised standard deviation of returns over the same period. Figures as of 7 Oct 2026.
From 2024 to 2026, the fund returned more than the BSE Healthcare Index in 2 of 3 calendar years. The 2026 figure is year to date.
| Year | 2024 | 2025 | 2026 YTD |
|---|---|---|---|
| This fund | +37.22% | +0.09% | +19.83% |
| Benchmark | +43.51% |
Wealth Home
Connect your mutual funds to see every holding in one place, how it is allocated, and how it is really doing.
Scan to connect on the app
iOS and Android. See your whole portfolio in a minute.
| -3.26% |
| +19.04% |
Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.